AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$25.07 USD
-0.40 (-1.57%)
Updated May 17, 2024 04:00 PM ET
After-Market: $25.01 -0.06 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
AnaptysBio, Inc. [ANAB]
Reports for Purchase
Showing records 141 - 154 ( 154 total )
Company: AnaptysBio, Inc.
Industry: Unclassified
Company: AnaptysBio, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: AnaptysBio, Inc.
Industry: Unclassified
Positive Top-line ANB019 Data De-Risks Program; Raising Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
ANB020 Establishes POC in Atopic Dermatitis, Taking our PT to $75
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
Company: AnaptysBio, Inc.
Industry: Unclassified
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: AnaptysBio, Inc.
Industry: Unclassified
Catalysts Abound, Were Buyers on Recent Weakness in Front of Data Filled Half
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
1Q, Recommending Shares Ahead of Significant Data Flow
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
Dupixent Price Suggests Higher Pricing for ANB020 Could be Achievable, Reiterate OUTPERFORM and Raising PT to $33
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
FY16 Financials, Multiple Data Readouts This Year, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
Scientific Presentations Highlight Role of IL- 33 Signaling in Allergic Diseases, Supports ANB020 Program, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AnaptysBio, Inc.
Industry: Unclassified
Initiating Coverage with an OUTPERFORM Rating and $28 Price Target: Making Great Antibodies Again
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D